紫杉醇脂质体联合奈达铂在中晚期宫颈癌同步放化疗中的应用(1)
【摘要】 目的：研究紫杉醇脂质体联合奈达铂同步放化疗治疗宫颈癌的临床疗效。方法：60例患者随机分为试验组和对照组，各30例，所有患者均接受相同剂量的放疗，试验组同时予紫杉醇脂质体联合奈达铂化疗，治疗结束后对两组患者的临床疗效及不良反应进行统计学分析。结果：试验组总有效率为93.3%，对照组总有效率为66.7%，差异有统计学意义(P<0.05)。试验组的3年生存率(0S)高于对照组(P<0.05)。试验组远处转移率明显低于对照组，差异有统计学意义(P<0.05)。试验组患者骨髓抑制和恶心呕吐不良反应明显高于对照组，差异有统计学意义(P<0.05)，但患者经对症处理后可耐受治疗。结论：紫杉醇脂质体联合奈达铂方案在中晚期宫颈癌同步放化疗中近期疗效明确，减少远处转移的风险，延长患者生存期，不良反应可耐受，值得临床进一步应用。
【关键词】 宫颈癌； 同步放化疗； 紫杉醇脂质体； 奈达铂
中图分类号 R711.74 文献标识码 A 文章编号 1674-6805(2015)6-0001-03
【Abstract】 Objective：To explore the clinical effect of Paclitaxel Liposome and Nedaplatin in advanced cervical cancer concurrent by radiochemotherapy.Method：60 patients were randomly divided into the experimental group(radiochemotherapy) and the control group(radiotherapy)，each group had 30 cases.All of patients were accepted the conventional radiatherapy，the patients of the experimental group were accepted concurrent radiochemotherapy.The clinica1 efficacy and adverse reactions in both groups were analyzed after treatment.Result：The experimental group overall response rate(CR+PR) was 93.3%，it was better than 66.7% of the control group(P<0.05)，and the over survival rate of 3 years were higher than the control group(P<0.05).The adverse reactions such as nausea and vomiting and bone marrow suppression in the experimental group patients were significantly higher than the control group patients(P<0.05).But after symptomatic treatment these patients all could complete the treatment plan.Conclusion：The result was shown that Paclitaxel Liposome and Nedaplatin concurrent by radiochemotherapy has clear short-term curative effect in advanced cervical cancer.That can reduce the risk of distant metastases，extend the patients survival，adverse reactions can be tolerated，which is worth further clinical application.
【Key words】 Cervical cancer； Concurrent radiochemotherapy； Paclitaxel Liposome； Nedaplatin
First-author’s address：The Tumour Hospital of Jiangsu Province，Nanjing 210009，China
doi：10.14033/j.cnki.cfmr.2015.06.001
宫颈癌是发展中国家最常见的妇科恶性肿瘤之一，其发病率在女性肿瘤中仅次于乳腺癌，成为女性第二大常见恶性肿瘤，严重威胁着妇女的健康[1]。近年来由于多种因素影响，宫颈癌的发病逐渐呈年轻化趋势，而且大多数患者就诊时已经处于中晚期。因此，提高宫颈癌的疗效有着非常重要的意义。目前，以单药顺铂为基础的同步放化疗已成为中晚期宫颈癌的标准治疗模式[2]。该治疗模式虽然可以有效提高患者的近期疗效和生存期，但是仍有部分中晚期患者在治疗后出现局部复发和远处转移[3]。因此，有学者提出在放疗同时联合全身化疗，可以预防局部复发和远处转移的风险[4]。本研究主要目的是比较紫杉醇脂质体联合奈达铂在同步放化疗中的疗效及安全性，以及减少局部复发和远处转移的作用，现将研究结果汇报如下。
1 资料与方法
1.1 一般资料
选取2010年1-12月由笔者所在科室收治的60例宫颈癌患者为研究对象，分期为Ⅱb～Ⅲb期(按照FIGO制定的标准进行临床分期)，所有患者均有组织学病理证实为宫颈癌，KPS评分>70分，年龄<60岁。临床实验室检查：WBC>4.0×109/L，HB>100 g/L，PLT>100×109 /L，肝, 百拇医药(朱必清 陆谔梅)
【关键词】 宫颈癌； 同步放化疗； 紫杉醇脂质体； 奈达铂
中图分类号 R711.74 文献标识码 A 文章编号 1674-6805(2015)6-0001-03
【Abstract】 Objective：To explore the clinical effect of Paclitaxel Liposome and Nedaplatin in advanced cervical cancer concurrent by radiochemotherapy.Method：60 patients were randomly divided into the experimental group(radiochemotherapy) and the control group(radiotherapy)，each group had 30 cases.All of patients were accepted the conventional radiatherapy，the patients of the experimental group were accepted concurrent radiochemotherapy.The clinica1 efficacy and adverse reactions in both groups were analyzed after treatment.Result：The experimental group overall response rate(CR+PR) was 93.3%，it was better than 66.7% of the control group(P<0.05)，and the over survival rate of 3 years were higher than the control group(P<0.05).The adverse reactions such as nausea and vomiting and bone marrow suppression in the experimental group patients were significantly higher than the control group patients(P<0.05).But after symptomatic treatment these patients all could complete the treatment plan.Conclusion：The result was shown that Paclitaxel Liposome and Nedaplatin concurrent by radiochemotherapy has clear short-term curative effect in advanced cervical cancer.That can reduce the risk of distant metastases，extend the patients survival，adverse reactions can be tolerated，which is worth further clinical application.
【Key words】 Cervical cancer； Concurrent radiochemotherapy； Paclitaxel Liposome； Nedaplatin
First-author’s address：The Tumour Hospital of Jiangsu Province，Nanjing 210009，China
doi：10.14033/j.cnki.cfmr.2015.06.001
宫颈癌是发展中国家最常见的妇科恶性肿瘤之一，其发病率在女性肿瘤中仅次于乳腺癌，成为女性第二大常见恶性肿瘤，严重威胁着妇女的健康[1]。近年来由于多种因素影响，宫颈癌的发病逐渐呈年轻化趋势，而且大多数患者就诊时已经处于中晚期。因此，提高宫颈癌的疗效有着非常重要的意义。目前，以单药顺铂为基础的同步放化疗已成为中晚期宫颈癌的标准治疗模式[2]。该治疗模式虽然可以有效提高患者的近期疗效和生存期，但是仍有部分中晚期患者在治疗后出现局部复发和远处转移[3]。因此，有学者提出在放疗同时联合全身化疗，可以预防局部复发和远处转移的风险[4]。本研究主要目的是比较紫杉醇脂质体联合奈达铂在同步放化疗中的疗效及安全性，以及减少局部复发和远处转移的作用，现将研究结果汇报如下。
1 资料与方法
1.1 一般资料
选取2010年1-12月由笔者所在科室收治的60例宫颈癌患者为研究对象，分期为Ⅱb～Ⅲb期(按照FIGO制定的标准进行临床分期)，所有患者均有组织学病理证实为宫颈癌，KPS评分>70分，年龄<60岁。临床实验室检查：WBC>4.0×109/L，HB>100 g/L，PLT>100×109 /L，肝, 百拇医药(朱必清 陆谔梅)